GlassScriptPhysician profile
Sara B Thacker
NPI 1720521917
$2,209.31
in general payments reported to CMS, 2019-2025
24 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,082 · 2022: $317 · 2023: $368 · 2024: $139 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $365.95 | 2021-2025 | Jardiance, Trulicity, Mounjaro |
| Abbvie INC. | $264.45 | 2021-2025 | |
| Novo Nordisk INC | $233.03 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $196.81 | 2021-2025 | Farxiga |
| Inari Medical, INC. | $194.33 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amarin Pharma, INC. | $155.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $123.24 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $92.02 | 2021 | |
| Amgen INC. | $82.86 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $70.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $62.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $49.54 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $41.00 | 2021 | |
| Daiichi Sankyo INC. | $40.08 | 2021-2024 | Injectafer |
| Exact Sciences Corporation | $36.01 | 2023-2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.32 | 2021 | |
| Organon LLC | $25.84 | 2025 | Nexplanon |
| Edwards Lifesciences Corporation | $25.76 | 2023 | |
| Insulet Corporation | $24.41 | 2024 | Omnipod |
| Alnylam Pharmaceuticals INC. | $22.73 | 2023 | Givlaari |
| Biohaven Pharmaceutical Holding Company LTD. | $22.22 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.73 | 2024 | |
| Corcept Therapeutics | $17.02 | 2025 | Korlym |
| Genentech USA, INC. | $10.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.